Technology

Teva’s TEV-408 Meets Primary Endpoint in Phase 2a Celiac Trial

Published

Courtroom-sketch editorial illustration of a stained small-bowel biopsy showing blunted intestinal villi and dense inflammatory cells, drawn in warm ochre and slate-blue pastel with cross-hatching on sepia newsprint.

Teva said TEV-408 met the primary endpoint in a randomized Phase 2a study of 50 adults with celiac disease on gluten-free diets. After one subcutaneous dose and a six-week gluten challenge, the mean villous-height-to-crypt-depth change was -0.43 with TEV-408 versus -0.88 with placebo, a 0.45 treatment difference that was statistically significant. Teva also reported lower intestinal immune-cell density and gastrointestinal symptom scores in the treatment group. The investigational anti-IL-15 antibody was well tolerated with no emerging safety signals, while further analyses continue.

Sources

Primary sources:1

Something went wrong

We couldn't complete that action. Check your connection and try again.